Daniel Rayson

Daniel Rayson

1278 Tower Road
Halifax, NS, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 113 publications

Pathological assessment of tumour beds in breast excisions post-neoadjuvant therapy: a retrospective cohort study.

Pathological assessment of tumour beds in breast excisions post-neoadjuvant therapy: a retrospective cohort study.

Journal: Histopathology
Published: January 19, 2026

Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study.

Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study.

Journal: Current oncology (Toronto, Ont.)
Published: October 17, 2025

Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada.

Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada.

Journal: Neuroendocrinology
Published: September 22, 2025

Seronegative Paraneoplastic Opsoclonus-Myoclonus-Ataxia Syndrome Secondary to Low Volume Endocrine-Sensitive Malignancy of Likely Breast Origin.

Seronegative Paraneoplastic Opsoclonus-Myoclonus-Ataxia Syndrome Secondary to Low Volume Endocrine-Sensitive Malignancy of Likely Breast Origin.

Journal: Current oncology (Toronto, Ont.)
Published: June 30, 2024

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.

Journal: Breast (Edinburgh, Scotland)
Published: December 14, 2023

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective.

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective.

Journal: Current oncology (Toronto, Ont.)
Published: July 05, 2023

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891-9895".

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891-9895".

Journal: Current oncology (Toronto, Ont.)
Published: March 15, 2023

Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review.

Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review.

Journal: Current oncology (Toronto, Ont.)
Published: February 03, 2023

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.

Journal: Current oncology (Toronto, Ont.)
Published: November 17, 2022

HER2 testing in metastatic breast cancer - Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?

HER2 testing in metastatic breast cancer - Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?

Journal: Annals of diagnostic pathology
Published: March 22, 2022

An end too soon?

An end too soon?

Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
Published: February 23, 2022

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.

Journal: Therapeutic advances in medical oncology
Published: August 27, 2021
Showing 1-12 of 113

Last Updated: 09/26/2026